BETA2,086.00

Beta Drugs Limited

· Unclassified
₹ CrorePeersTHEJOMACPOWERSAKARSERVOTECHMcap ₹2,115 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)124.12156.37156.37
Receivable Days (DSO)103.33112.99112.99
Payable Days (DPO)148.01169.31131.36
Cash Conversion Cycle (days)79.44100.05138.00
Working Capital Turnover1.591.702.25
Asset Turnover0.830.780.78
Cash Conversion (CFO/Net Income)0.750.900.90
CFO/EBITDA0.420.490.49
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.